Currently, there are 205.10M common shares owned by the public and among those 164.03M shares have been available to trade.
The company’s stock has a 5-day price change of 7.27% and -25.43% over the past three months. HIMS shares are trading 94.04% year to date (YTD), with the 12-month market performance up to 187.35% higher. It has a 12-month low price of $5.65 and touched a high of $25.74 over the same period. HIMS has an average intraday trading volume of 8.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.62%, -0.68%, and 17.43% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 56.85% of the company’s 205.10M shares outstanding.
It has a market capitalization of $3.74B and a beta (3y monthly) value of 1.05. The stock’s trailing 12-month PE ratio is 230.88, while the earnings-per-share (ttm) stands at $0.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.52% over the week and 4.75% over the month.
Analysts forecast that Hims & Hers Health Inc (HIMS) will achieve an EPS of 0.04 for the current quarter, 0.07 for the next quarter and 0.37 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.04 while analysts give the company a high EPS estimate of -0.04. Comparatively, EPS for the current quarter was -0.04 a year ago. Earnings per share for the fiscal year are expected to increase by 469.09%, and 83.04% over the next financial year.
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on August 22, 2024, with the firm’s price target at $24. Citigroup was of a view on May 22, 2024 that the stock is Neutral, while Jefferies gave the stock Hold rating on April 16, 2024, issuing a price target of $17- $15. Canaccord Genuity on their part issued Buy rating on April 10, 2024.
